Citius Oncology, Inc. (CTOR)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on CTOR

With Tiblio's Option Bot, you can configure your own wheel strategy including CTOR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CTOR
  • Rev/Share 0.0
  • Book/Share 0.5771
  • PB 1.681
  • Debt/Equity 0.092
  • CurrentRatio 0.3936
  • ROIC 0.0

 

  • MktCap 69405828.0
  • FreeCF/Share -0.0051
  • PFCF -190.6439
  • PE -10.4225
  • Debt/Assets 0.042
  • DivYield 0
  • ROE -0.1485

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CTOR
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024.

Read More
image for news Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CTOR, CTXR
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.

Read More
image for news Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

About Citius Oncology, Inc. (CTOR)

  • IPO Date
  • Website None
  • Industry Drug Manufacturers - General
  • CEO Mr. Leonard L. Mazur
  • Employees None
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.